AI-Designed mRNA vaccine takes on advanced tumors in first human test
NCT ID NCT07560943
First seen May 03, 2026 · Last updated Jun 23, 2026 · Updated 14 times
Summary
This early-phase trial tests a new mRNA vaccine called PAN-NeoVax, designed by artificial intelligence to target multiple cancer types. The vaccine is injected directly into tumors in 9 patients with advanced solid cancers who have run out of standard options. The main goal is to check safety and find the right dose, with a secondary look at whether the vaccine can shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The West China Hospital
RECRUITINGChengdu, Sichuan, 646000, China
-
West China Hospital
NOT_YET_RECRUITINGChengdu, Sichuan, 610000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PAN-NeoVax (an AI-designed mRNA vaccine)
What this could lead to
If successful, this could point toward a new way to train the immune system to fight advanced cancers that have not responded to other treatments.
What could go wrong
This is a very early, small Phase 1 trial with only 9 participants. The vaccine may not shrink tumors or may cause side effects. Success is far from guaranteed.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.